| Followers | 843 |
| Posts | 122802 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, November 29, 2007 5:29:07 PM
IDIX’s BoD. This was expected inasmuch as Ebeling was
recently demoted from head of NVS’ pharma division to
head of its consumer division (#msg-23784225).
http://biz.yahoo.com/e/071129/idix8-k.html
>>
On November 23, 2007, Novartis Pharma AG ("Novartis") nominated Emmanuel Puginier, M.D. as one of its two designees to the Board of Directors (the "Board") of Idenix Pharmaceuticals, Inc. (the "Company"). Previously, Mr. Thomas Ebeling and Mr. Robert Pelzer had served as Novartis' two designees to the Company's Board. Mr. Pelzer will remain on the Board as a Novartis designee.
Dr. Puginier, who currently holds the position of Global Head of Marketing and Sales General Medicines at Novartis, is expected to serve on the Compensation Committee of the Board. Mr. Pelzer will continue to serve as a non-voting observer to each of the Audit Committee and Nominating and Corporate Governance Committee of the Board. Neither Dr. Puginier nor Mr. Pelzer will receive any compensation for their services as directors on the Board.
<<
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
